Characteristics and clinical influence factors of arsenic species in plasma and their role of arsenic species as predictors for clinical efficacy in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide

Guo, Meihua1; Zhou, Jin2; Fan, Shengjin3; Li, Limin2; Chen, Hongzhu1; Lin, Liwang1; Zhao, Qilei1; Wang, Xinyu1; Liu, Wensheng1; Wu, Zhiqiang1; Hai, Xin1

2021-03-01

10.1080/17512433.2021.1893940

Expert Review of Clinical Pharmacology   影响因子和分区

1751-2433

1751-2441

["Background: Arsenic trioxide (ATO) is successfully applied to treat acute promyelocytic leukemia (APL). Arsenic species levels in blood are critical to reveal metabolic mechanism and relationship between arsenic species and clinical response. Characteristics and influence factors of arsenic species in APL patients have not been studied.","Methods: 305 plasma samples from APL patients treated with ATO were analyzed using HPLC-HG-AFS. Trough concentration (C-trough), distribution, methylation levels of arsenic species were evaluated. The influence factors on arsenic species levels of plasma and association between arsenic concentrations and clinical efficacy were explored.","Results: C-trough of arsenic in effective treatment groups provide basis for defining the target range of arsenic plasma concentrations in APL patients treated with ATO. Distribution trends: DMA(V) > As-III, MMA(V)> As-V (p < 0.0001) for continuous slow-rate (CS) infusion and DMA(V) > MMA(V) > As-III > As-V (p < 0.0001) for conventional infusion. Infusion methods and combined medication may affect arsenic metabolism. There was a weak correlation between ATO dose and plasma C-trough of arsenic species. C-trough of plasma arsenic species had predictive value for treatment efficacy.","Conclusion: Arsenic concentration monitoring in APL patients treated with ATO is required. These findings are critical to optimize treatment outcomes of ATO therapy."]

Arsenic trioxide arsenic species efficacy prediction arsenic concentration monitoring acute promyelocytic leukemia

SCI

英语

其他

National Natural Science Foundation of China[81700151] ; Natural Science Foundation of Heilongjiang Province for Excellent Youths[YQ2019H016] ; Excellent Youth Foundation of First Affiliated Hospital of Harbin Medical University[HYD2020JQ0018] ; Foundation of First Affiliated Hospital of Harbin Medical University[2019M15] ; Foundation of Health Commission of Heilongjiang Province[2017-029] ; Bethune Medical Science Research Fund[SCZ167EN]

Pharmacology & Pharmacy

Pharmacology & Pharmacy

WOS:000626399100001

TAYLOR & FRANCIS LTD

Web of Science

1.Harbin Med Univ, Affiliated Hosp 1, Dept Pharm, 23 Youzheng Str, Harbin 150001, Peoples R China
2.Southern Univ Sci & Technol Hosp, Dept Hematol, Shenzhen, Peoples R China
3.Harbin Med Univ, Affiliated Hosp 1, Dept Hematol, Harbin, Peoples R China

Guo, Meihua,Zhou, Jin,Fan, Shengjin,et al. Characteristics and clinical influence factors of arsenic species in plasma and their role of arsenic species as predictors for clinical efficacy in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide[J]. Expert Review of Clinical Pharmacology,2021.

Guo, Meihua.,Zhou, Jin.,Fan, Shengjin.,Li, Limin.,Chen, Hongzhu.,...&Hai, Xin.(2021).Characteristics and clinical influence factors of arsenic species in plasma and their role of arsenic species as predictors for clinical efficacy in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide.Expert Review of Clinical Pharmacology.

Guo, Meihua,et al."Characteristics and clinical influence factors of arsenic species in plasma and their role of arsenic species as predictors for clinical efficacy in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide".Expert Review of Clinical Pharmacology (2021).